Protocols

GSK vet Deborah Waterhouse takes CEO spot at Viiv; Is Sanofi pondering an Actelion bid?

Deborah Waterhouse

Deborah Waterhouse

GSK insider Deborah Waterhouse, currently an SVP running the primary care ops of the US pharma division, has been tapped as the new CEO of Viiv, an ambitious joint venture focused on HIV. A 20-year veteran, Waterhouse is taking the place of Dominique Limet, who departs at the end of March. Viiv has been able to make significant progress in adding new products and growing sales, making it a key part of the GSK organization. It’s partnered with Pfizer on the group.

Sanofi is now rumored to be pondering a move to bid for Actelion, currently in buyout talks with J&J. Bloomberg reports that the French pharma giant may sweeten J&J’s offer of $250 a share, which values the Swiss biotech at $27 billion. That would be a couple of steps past Sanofi’s frequently repeated plan to limit M&A to $20 billion. But after being forced to watch Pfizer step in and buy Medivation, Sanofi may be altering its takeover math.

Belgian stem cell biotech TiGenix has set terms for a $53 million IPO. The 16-year-old biotech plans to list on Nasdaq under $TIG.

AbbVie has stepped in to partner with researchers at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University along with a separate group at Johns Hopkins. They’ll be collaborating on several areas of oncology research, which in addition to others could include, lung, colorectal, breast, prostate and hematological cancer. The work at Northwestern will be overlooked by a joint steering committee, with an annual symposium to review their progress.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Regulatory Convergence 2017